Dr. Rymer is currently researching regulation of movement in normal and neurologically disordered human subjects, including sources of altered motoneuronal behavior in hemispheric stroke survivors, using electro-physiological, pharmacological, and biomechanical techniques. He currently serves as Director of the Single Motor Unit Laboratory of the Shirley Ryan AbilityLab (SRALab, formerly known as the Rehabilitation Institute of Chicago, or RIC). From 1987-2017 he served as Director of the Sensory Motor Performance Program at RIC, and was RIC’s Vice President for Research from 2008-2014. He is the most senior scientist at SRALab and the founder of many of its current research programs. Dr. Rymer has established himself as one of the most successful mentors of junior faculty, and has been able to relate to the many backgrounds that can contribute to rehabilitation research. In addition to his roles at SRALab, he holds appointments as Professor of PM&R, Physiology, and Biomedical Engineering at the Northwestern University Feinberg School of Medicine.
In addition to adverse reactions reported from clinical trials, the following adverse reactions have been identified during postapproval use of albuterol sulfate. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These events have been chosen for inclusion due to either their seriousness, frequency of reporting, or causal connection to albuterol or a combination of these factors.
to mg via oral inhalation every 4 to 6 hours as needed for symptoms of bronchospasm is recommended by the National Asthma Education and Prevention Program (NAEPP) Expert Panel. For acute asthma exacerbations, the NAEPP recommends mg/kg/dose (Min: mg/dose) via oral inhalation every 20 minutes for 3 doses, then to mg/kg/dose (Max: 10 mg/dose) every 1 to 4 hours as needed or mg/kg/hour by continuous nebulization. The Global Initiative for Asthma (GINA) guidelines recommend mg via nebulization with mouthpiece (and facemask in those younger than 4 years) every 20 minutes for the first hour for acute exacerbations, with reassessment thereafter (further dosing not specified). According to FDA-approved labeling, initial dosing for albuterol % solution is to mg/kg/dose, with subsequent dosing titrated to achieve desired clinical response. Max: mg/dose 3 to 4 times daily; do not exceed 4 doses/day. For patients weighing at least 15 kg, the % solution may be used at a dose of mg via oral inhalation 3 to 4 times daily as needed. Doses should be delivered over 5 to 15 minutes.